{"filing":{"accession_number":"0000875320-26-000256","cik":"0000875320","ticker":"VRTX","company_name":"VERTEX PHARMACEUTICALS INC / MA","form":"8-K","filing_date":"2026-08-03","report_date":"2026-08-03","primary_document":"vrtx-20260803.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000256/vrtx-20260803.htm"},"events":[{"id":23279,"run_id":21049,"accession_number":"0000875320-26-000256","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a clear earnings release disclosing Vertex's consolidated financial results for Q2 2026 (three and six months ended June 30, 2026), including total revenue of $3.33 billion (12% increase YoY), net income, and updated full-year 2026 revenue guidance raised to $13.1–$13.2 billion. The press release is attached as Exhibit 99.1 and filed under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures.","company_name":"VERTEX PHARMACEUTICALS INC / MA","ticker":"VRTX","filing_date":"2026-08-03","form":"8-K","submitted_at":null,"items":[{"id":23472,"accession_number":"0000875320-26-000256","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Vertex's consolidated financial results for Q2 2026 (three and six months ended June 30, 2026), including total revenue of $3.33 billion (12% increase YoY), net income, and updated full-year 2026 revenue guidance raised to $13.1–$13.2 billion. The press release is attached as Exhibit 99.1 and filed under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T02:16:40.333412+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":23472,"accession_number":"0000875320-26-000256","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Vertex's consolidated financial results for Q2 2026 (three and six months ended June 30, 2026), including total revenue of $3.33 billion (12% increase YoY), net income, and updated full-year 2026 revenue guidance raised to $13.1–$13.2 billion. The press release is attached as Exhibit 99.1 and filed under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T02:16:40.333412+00:00","company_name":"VERTEX PHARMACEUTICALS INC / MA","ticker":"VRTX","filing_date":"2026-08-03"}]}